Kairos Pharma, LTD. (NYSE: KAPA)

Kairos Pharma, Ltd. is a clinical stage biopharmaceutical company focused on developing therapeutics that overcome immune suppression and drug resistance in cancer. The company creates antibody and small molecule drug candidates aimed at treating prostate cancer, lung cancer, breast cancer and glioblastoma. Its pipeline consists of seven drug candidates, including five internally discovered molecules that modulate immune response and two assets acquired through its Enviro Therapeutics subsidiary that target the tumor microenvironment. All programs are currently in pre clinical or clinical stages and have not yet received regulatory approval.

As a pre revenue company Kairos Pharma, Ltd. does not currently generate sales from approved products. The company funds its research and development activities through equity offerings, grant funding and strategic collaborations. No product revenue has been reported to date.

Within the oncology therapeutic landscape Kairos Pharma, Ltd. positions itself as a developer of treatments that address both cancer cells and the supportive tumor microenvironment. The company competes with large pharmaceutical firms that sell immune checkpoint inhibitors and targeted therapies, while seeking to differentiate through its dual targeting approach and its pipeline of novel mechanisms. Its lead asset ENV 105 is designed to counteract resistance mechanisms seen in prostate and lung cancer therapies.

The company intends to serve patients with advanced prostate lung breast and brain cancers as well as the hospitals and clinics that administer cancer therapies. Its clinical trial partners include academic medical centers such as Cedars Sinai Medical Center University of Utah and City of Hope. No commercial customers exist at this stage because the product candidates remain investigational.